Aflac Incorporated (NYSE: AFL) is scheduled to announce its second-quarter earnings for 2025 on August 5, 2025, after the market closes. Analysts predict the company will report earnings of $1.73 per share, alongside revenues of approximately $4.30 billion for the quarter. As anticipation builds, Aflac’s stock has experienced a slight decline of 1.3%, opening at $98.10 on Monday.
The company currently boasts a market capitalization of $53.04 billion, with a price-to-earnings ratio of 15.33 and a PEG ratio of 3.03. The stock’s performance has been relatively stable, evidenced by its 50-day simple moving average of $102.58 and a 200-day simple moving average of $105.05. Over the past year, Aflac’s stock has fluctuated between a low of $95.97 and a high of $115.50.
Insider Trading Activity Raises Questions
In related news, recent insider trading activity has caught the attention of market analysts. On May 8, 2025, Director Joseph L. Moskowitz sold 1,000 shares of Aflac stock at an average price of $106.79, totaling $106,790. Following this transaction, Moskowitz holds 26,096 shares valued at approximately $2.79 million, marking a 3.69% reduction in his ownership.
Another significant transaction occurred on May 15, 2025, when Director Arthur Reginald Collins sold 2,750 shares at an average price of $105.70, amounting to $290,675. Collins now maintains 6,728 shares, worth about $711,149.60, reflecting a 29.01% decrease in his stake. In total, insiders have sold 40,750 shares in the past quarter, valued at around $4.3 million. Corporate insiders now hold 0.80% of Aflac’s stock.
Analysts Adjust Ratings Ahead of Earnings Report
As Aflac prepares for its earnings announcement, various brokerages have provided updated ratings for the stock. On July 7, 2025, Barclays set a price target of $98.00 and assigned an “underweight” rating. In contrast, JPMorgan Chase & Co. recently raised its price target from $96.00 to $100.00, maintaining a “neutral” rating.
Further adjustments include a downgrade from “hold” to “sell” by Wall Street Zen on May 5, 2025. Meanwhile, Keefe, Bruyette & Woods increased their target from $104.00 to $106.00, and Raymond James Financial lowered their price objective from $115.00 to $110.00 while retaining an “outperform” rating. Currently, Aflac holds an average rating of “Hold” with a consensus target price of $108.15, based on data from MarketBeat.com.
Aflac Incorporated, through its subsidiaries, specializes in providing supplemental health and life insurance products. The firm operates primarily through its segments in Japan and the United States, offering a range of insurance products, including cancer and medical insurance, nursing care, and life insurance.
As the market awaits Aflac’s earnings report, investors will closely monitor the results to gauge the company’s performance amidst shifting analyst sentiments and insider trading activities.